ArticleTranslational lung cancer research2025
Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic significance of TTF-1 expression in advanced lung adenocarcinoma may be an important factor in optimizing treatment strategies. This study aimed to evaluate the impact of TTF-1 negativity on overall survival (OS) and progression-free survival (PFS) in stage IV lung adenocarcinoma patients with low PD-L1 expression treated with platinum-pemetrexed-pembrolizumab. Methods: We conducted a retrospective analysis of 155 patients with stage IV lung adenocarcinoma and PD-L1 expression <50%. We stratified patients according to TTF-1 expression. The primary survival analysis focused on 64 patients who received first-line platinum-pemetrexed chemotherapy in combination with pembrolizumab. We evaluated OS and PFS using Kaplan-Meier curves and multivariate Cox regression. Results: Among patients treated with platinum-pemetrexed-pembrolizumab, TTF-1-negative patients showed significantly shorter OS and numerically shorter PFS compared to TTF-1-positive patients. Median OS was 13 months for TTF-1-negative patients and 21 months for TTF-1-positive patients (P=0.01). Median PFS was 10 Conclusions: TTF-1 negativity is an independent adverse prognostic factor in patients with stage IV lung adenocarcinoma and low PD-L1 expression. The observed differences in survival suggest that platinum-pemetrexed-pembrolizumab may be less effective for TTF-1-negative patients, and that alternative strategies should be explored in this high-risk subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.